['diffuse large b-cell lymphoma']
['selinexor']

        Inclusion Criteria:

          -  Age ≥18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

          -  Pathologically confirmed de novo DLBCL

          -  Objective, documented evidence of disease progression on study entry

          -  Have previously received at least 2 but no more than 5 previous systemic regimens for
             the treatment of DLBCL

          -  Have measurable disease

          -  For patients whose most recent anti-DLBCL therapy induced a PR or CR, at least 60 days
             must have elapsed since the end of that therapy. For all other patients, at least 14
             weeks must have elapsed since their most recent systemic anti-DLBCL therapy

        Exclusion Criteria:

          -  DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma
             (HL+NHL) or DLBCL transformed from diseases other than indolent NHL

          -  Must not be eligible for high-dose therapy with autologous stem cell transplantation
             rescue

          -  Primary mediastinal (thymic) large B-cell lymphoma (PMBL)

          -  Known central nervous system (CNS) lymphoma

          -  Active Hepatitis B or C infection

          -  Known human immunodeficiency virus (HIV) infection

          -  Unable to swallow tablets, patients with malabsorption syndrome, or any other GI
             disease or GI function that could interfere with absorption of study treatment
      